Regarding hormone receptor and Her2 status, according to the data on a study of the German Consortium for Hereditary Breast and Ovarian Cancer, a high CHEK2 mutation prevalence was observed in patients with Her2-positive tumors compared with patients with Her2-negative tumors (5.2% vs. 2.3%; p-value <0.001). This evidence concerns the gene CHEK2 and neoplasm.